Kymera Therapeutics, Inc. (KYMR) stock analysis

In our weekly check, Kymera Therapeutics, Inc. is graded F (A to F). Of 22 checks on debt, profit, cash flow and trend: 6 pass, warnings: 2, red flags: 14.

About Kymera Therapeutics, Inc.

Kymera Therapeutics, Inc. is a Healthcare company (Biotechnology) based in the United States, listed on NASDAQ as KYMR.

What our checks show for KYMR

Red flags

Warning signs

Strengths

Similar companies

BMRN · SMMT · HALO · TECH · PCVX · MDGL

Questions

What grade does Kymera Therapeutics, Inc. (KYMR) have?

In our weekly check, Kymera Therapeutics, Inc. is graded F (A to F). Of 22 checks on debt, profit, cash flow and trend: 6 pass, warnings: 2, red flags: 14. The grade is a risk check, not a buy or sell recommendation.

What are the main risks of KYMR stock?

This week's biggest flags for Kymera Therapeutics, Inc.: Weak interest cover, Margins falling, Weak EPS forecast. In total 16 of 22 checks show a warning or a red flag.

What does Kymera Therapeutics, Inc. do?

Kymera Therapeutics, Inc. is a Healthcare company (Biotechnology) based in the United States, listed on NASDAQ as KYMR.

The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.

Updated 2026-11-14

Open the full analysis